Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines Nino KeshelavaSusan GroshenC. Patrick Reynolds ORIGINAL ARTICLE Pages: 1 - 8
Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance Helen M. DoddsStephen J. ClarkeLaurent P. Rivory ORIGINAL ARTICLE Pages: 9 - 14
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts Mark R. MiddletonJane KellyGeoffrey P. Margison ORIGINAL ARTICLE Pages: 15 - 20
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models Corrie E.M. GiddingGlen S. GermainPeter J. Houghton ORIGINAL ARTICLE Pages: 21 - 30
Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide Tiziana ZaccheoDonata GiudiciEnrico di Salle ORIGINAL ARTICLE Pages: 31 - 37
Interaction between gemcitabine and mitomycin-C in vitro Tu T. AungMary A. DavisTheodore S. Lawrence ORIGINAL ARTICLE Pages: 38 - 42
Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines R. KröningA. K. LichtensteinG. T. Nagami ORIGINAL ARTICLE Pages: 43 - 49
Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver Peter PlatzerTheresia ThalhammerWalter Jäger ORIGINAL ARTICLE Pages: 50 - 54
A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer Lorraine K. WebsterIan N. OlverJames F. Bishop ORIGINAL ARTICLE Pages: 55 - 58
DNA guanine-guanine crosslinking sequence specificity of isophosphoramide mustard, the alkylating metabolite of the clinical antitumor agent ifosfamide R. F. StruckR.L. Davis Jr.E. L. Loechler ORIGINAL ARTICLE Pages: 59 - 62
Variability of cyclophosphamide uptake into human bronchial carcinoma: consequences for local bioactivation Frank BohnenstengelGodehard FriedelHeyo K. Kroemer ORIGINAL ARTICLE Pages: 63 - 68
Potentiation of BCNU antitumor efficacy by 9-substituted O 6-benzylguanines. Effect of metabolism D. M. KokkinakisR. C. MoschelS. C. Schold ORIGINAL ARTICLE Pages: 69 - 77
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells Hans MindermanCarol WrzosekYoucef M. Rustum ORIGINAL ARTICLE Pages: 78 - 84
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG) S. AamdalB. LundJ. Verweij CLINICAL TRIAL REPORT Pages: 85 - 88
Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients E. FokkemaE.G.E. de VriesH. J. M. Groen SHORT COMMUNICATION Pages: 89 - 92